This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Freeline Therapeutics Holdings Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Michael Parini

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage	27.4%
CEO tenure	2yrs
CEO ownership	1.1%
Management average tenure	1.6yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Michael Parini's remuneration changed compared to Freeline Therapeutics Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2023	n/a	n/a	-US$61m
Dec 31 2022	US$2m	US$591k	-US$89m
Sep 30 2022	n/a	n/a	-US$101m
Jun 30 2022	n/a	n/a	-US$117m
Mar 31 2022	n/a	n/a	-US$132m
Dec 31 2021	US$1m	US$419k	-US$140m

Compensation vs Market: Michael's total compensation ($USD2.16M) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Parini (48 yo)

2yrs

Tenure

US$2,160,000

Compensation

Mr. Michael J. Parini, JD., serves as Chief Executive Officer & Executive Director at Freeline Therapeutics Limited since August 16, 2021. He had been President and Chief Operating Officer at Freeline Ther...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Parini	CEO & Executive Director	2yrs	US$2.16m	1.1% € 180.7k
Paul Schneider	CFO & Director	1.3yrs	no data	no data
Henning Stennicke	Chief Scientific Officer	1.4yrs	no data	no data
Nicole Jones	Chief People Officer	1.1yrs	no data	no data
James Bircher	Chief Technical Operations Officer	2.1yrs	no data	no data
Pamela Foulds	Chief Medical Officer	1.8yrs	no data	no data
Naomi Aoki	Senior Vice President of Corporate Communications & Investor Relations	no data	no data	no data
Amy Spandau	Interim Head of Finance	no data	no data	no data

1.6yrs

Average Tenure

52yo

Average Age

Experienced Management: 78F0's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Parini	CEO & Executive Director	2yrs	US$2.16m	1.1% € 180.7k
Paul Schneider	CFO & Director	less than a year	no data	no data
Julia Gregory	Independent Non-Executive Director	3.8yrs	US$172.00k	no data
Colin Love	Independent Non Executive Director	2.4yrs	US$93.00k	no data
Christopher Hollowood	Independent Chairman	7.7yrs	US$93.00k	no data
Jeffrey Chodakewitz	Independent Non-Executive Director	4yrs	US$166.00k	no data
Martin Andrews	Independent Non-Executive Director	4.8yrs	US$154.00k	no data

3.8yrs

Average Tenure

59yo

Average Age

Experienced Board: 78F0's board of directors are considered experienced (3.8 years average tenure).

This company listing is no longer active

Freeline Therapeutics Holdings Management

Management criteria checks 1/4

Key information

Recent management updates

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2023

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2022

Freeline Therapeutics Holdings plc Appoints Paul Schneider as Chief Financial Officer

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

High number of new directors

Recent updates

Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Freeline Therapeutics Files Form 15

Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index

Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN).

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for for $9.8 million.

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for approximately $140 million.

Freeline Therapeutics Holdings plc Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 Galileo-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Freeline Therapeutics Holdings plc Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-Linked Parkinson's Disease

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2023

Freeline Therapeutics Holdings Regains Compliance with the Nasdaq Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc Receives ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

Freeline Therapeutics Holdings plc Announces the Publication of Preclinical Proof-Of-Concept Data for Its Gene Therapy Candidate for Fabry Disease, FLT190

Freeline Initiates Dosing of Second Cohort in Marvel-1 Trial of Flt190 Gene Therapy Candidate for People with Fabry Disease

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2022

Freeline Therapeutics Holdings plc Appoints Paul Schneider as Chief Financial Officer

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

Freeline Therapeutics Holdings plc Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

Freeline Therapeutics Holdings plc Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial

High number of new directors

Chief Scientific Officer Romuald Corbau has left the company

CEO & Director Theresa Heggie has left the company

Chief Development Officer Jan Thirkettle has left the company

Freeline Doses Second Patient of Phase 1/2 Marvel-1 Clinical Trial for Fabry Disease

Freeline Therapeutics Holdings plc Presents Data Highlighting Platform Technology At the American Society of Gene and Cell Therapy Annual Meeting 2021

CFO & Head of Corporate Development has left the company

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age